Pharmacological inhibition of EGFR signaling, using drugs such as AG-1478, gefitinib, or BIBX1522, has been demonstrated to reduce MCM in both acute and chronic asthma models (6, 53–55), suggesting a contributory role of EGFR in MCM. This evidence concerns the gene EGFR and chronic asthma.